| Literature DB >> 35697848 |
Håvard Hynne1, Behzod Tashbayev2, My Tien Diep3, Anne Thea Tveit Sødal3, Reza A Badian4, Xiangjun Chen2, Xiaoran Lai5, Tor P Utheim6,7, Lene Hystad Hove3, Janicke Liaaen Jensen2.
Abstract
In the present study, the relationship between dry eyes and dry mouth was explored in 150 65-year-old subjects randomly selected from the general population in Oslo, Norway. The number of drugs, including xerogenic drugs, and current and previous systemic diseases were recorded. Ocular parameters recorded were the McMonnies Dry Eye Questionnaire, the Ocular Surface Disease Index, the Schirmer I Test, tear film break-up time and ocular surface staining. The oral parameters were xerostomia frequency, Summated Xerostomia Inventory, Clinical Oral Dryness Score, and unstimulated and stimulated whole saliva. The participants with current or previous systemic diseases had significantly more ocular and oral symptoms and significantly more oral clinical findings than the participants without a history of disease. Moreover, correlation and factor analyses demonstrated an association between subjective ocular and oral parameters. A significant correlation between the total number of drugs and the presence of ocular and oral symptoms was also noted. When the participants were categorized based on their ocular symptoms, poorer values were found for the oral parameters among the participants more troubled with dry eyes. The results in the present study call for increased awareness and an interdisciplinary approach in matters related to dry eyes and dry mouth.Entities:
Mesh:
Year: 2022 PMID: 35697848 PMCID: PMC9191758 DOI: 10.1038/s41598-022-13985-6
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.996
Figure 1Flow diagram illustrating the recruitment process.
Mean values, SD, minimum, maximum, and missing values for ocular, oral and drug parameters.
| Ocular parameters | Oral parameters | Number of drugs | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDEQ | OSDI | ST | TFBUT | OSS | XF | SXI | CODS | UWS | SWS | ND | NXD | |
| n | 148 | 149 | 146 | 139 | 150 | 150 | 150 | 150 | 150 | 148 | 150 | 150 |
| Mean | 6.3 | 8.3 | 12.4 | 9.0 | 0.8 | 1.6 | 6.7 | 2.0 | 0.4 | 1.9 | 2.5 | 0.7 |
| ± SD | 4.0 | 11.3 | 8.6 | 6.2 | 1.2 | 0.7 | 1.7 | 1.3 | 0.3 | 0.9 | 2.8 | 1.2 |
| Minimum | 0 | 0 | 2 | 0 | 0 | 1 | 5 | 0 | 0.04 | 0.24 | 0 | 0 |
| Maximum | 20 | 64 | 36 | 36 | 5 | 4 | 15 | 6 | 1.3 | 4.9 | 13 | 8 |
| Missing | 2 | 1 | 4 | 11 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
MDEQ McMonnies Dry Eye Questionnaire, OSDI Ocular Surface Disease Index, ST Schirmer I Test (mm/5 min), TFBUT tear film break-up time, OSS ocular surface staining, XF xerostomia frequency, SXI summated xerostomia inventory, CODS clinical oral dryness score, UWS unstimulated whole saliva (mL/min), SWS stimulated whole saliva (mL/min), ND number of drugs, NXD number of xerogenic drugs.
Demographic characteristics of participants (n = 150).
| Number of participants | |
|---|---|
| Male | 68 (45%) |
| Female | 82 (55%) |
| West-European | 140 (93%) |
| Other | 10 (7%) |
| Basic | 6 (4%) |
| Secondary | 44 (30%) |
| Higher | 100 (66%) |
| Diseases of the circulatory system | 16 (10%) |
| Cancer | 21 (14%) |
| Others | 3 (2%) |
| No previous disease | 111 (74%) |
| Diseases of the respiratory system | 15 (10%) |
| Diseases of the musculoskeletal system/connective tissue | 28 (19%) |
| Cancer | 6 (4%) |
| Diseases of the circulatory system | 48 (32%) |
| Endocrine, nutritional and metabolic diseases | 10 (7%) |
| Others | 36 (24%) |
| No current disease | 118 (78%) |
| ≥ 5 drugs | 28 (19%) |
| < 5 drugs | 122 (81%) |
Number of subjects with pathological levels of ocular and oral variables.
| n | ||
|---|---|---|
| Ocular | OSDI > 12 | 41 |
| MDEQ > 10.5 | 24 | |
| TFBUT ≤ 10 | 96 | |
| TFBUT ≤ 5 | 59 | |
| ST ≤ 10 | 73 | |
| OSS ≥ 1 | 68 | |
| Oral | SXI > 10 | 5 |
| XF ≥ 3 | 12 | |
| UWS ≤ 0.1 | 12 | |
| SWS ≤ 0.7 | 7 |
OSDI ocular surface disease index, MDEQ McMonnies Dry Eye Questionnaire, TFBUT tear film break-up time, ST Schirmer I Test (mm/5 min), OSS ocular surface staining, SXI summated xerostomia inventory, XF xerostomia frequency, UWS unstimulated whole saliva (mL/min), SWS stimulated whole saliva (mL/min).
Figure 2Significant correlations when comparing patient-reported and clinical ocular and oral findings (p < 0.05). Ocular parameters: MDEQ McMonnies Dry Eye questionnaire, OSDI Ocular Surface Index questionnaire, TFBUT tear film break up time (s), OSS ocular surface staining, ST Schirmer I test (mm/5 min). Oral parameters: UWS unstimulated whole saliva (ml/min), SWS stimulated whole saliva(ml/min), CODS Clinical Oral Dryness Score, SXI summated xerostomia inventory, XF oral dryness frequency, ND number of drugs, NXD number of xerogenic drugs.
Comparison of oral parameters between subgroups of OSDI Ocular Surface Index questionnaire and MDEQ McMonnies Dry Eye questionnaire respectively.
| n | UWS | SWS | CODS | SXI | XF | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | SD | Mean | SD | Mean | SD | Mean | SD | Mean | SD | ||
| OSDI (0–12) | 107 | 0.4 | 0.3 | 1.9 | 0.9 | 2 | 1.3 | 1.5 | 0.6 | ||
| OSDI (13–22) | 22 | 0.3 | 1.8 | 1.7 | 0.6 | 1.6 | 1.4 | 7.3 | 2 | 0.7 | |
| OSDI (23–32) | 13 | 0.3 | 0.2 | 1.9 | 1 | 2 | 1.1 | 7 | 2 | 1.7 | 0.8 |
| OSDI (33–100) | 6 | 0.3 | 0.2 | 1.6 | 0.5 | 3 | 1.4 | 2.1 | 1 | ||
| MDEQ (0–10.5) | 123 | 0.2 | 1.9 | 0.9 | 1.3 | 6.5 | 1.5 | 0.6 | |||
| MDEQ (> 10.5) | 24 | 0.2 | 1.6 | 0.8 | 1.4 | 7.4 | 2.4 | 0.9 | |||
ANOVA with Bonferroni Post Hoc test.
Bold represents level of significance: p < 0.05.
1SXI Summated Xerostomia Inventory, OSDI 0–12 vs. OSDI 33–100, p = 0.016.
2XF xerostomia frequency, OSDI 0–12 vs. OSDI 13–22, p = 0.032.
3XF, OSDI 0–12 vs. OSDI 33–100, p = 0.023 Mann–Whitney U test of relationship MDEQ ≤ 10.5 vs. MDEQ > 10.5 and oral parameters.
4UWS unstimulated whole saliva (ml/min), p = 0.04.
5CODS Clinical Oral Dryness score, p = 0.032.
6XF, p = 0.002.
Correlation between pathological levels of ocular and oral parameters.
| Ocular | Oral | ||||
|---|---|---|---|---|---|
| SXI > 10 | XF > 3 | UWS ≤ 0.1 | SWS ≤ 0.7 | ND ≥ 5 | |
| r | 0.22 | 0.15 | 0.02 | − 0.05 | 0.17 |
| p-value | 0.07 | 0.84 | 0.52 | ||
| r | 0.22 | 0.21 | − 0.14 | − 0.13 | 0.30 |
| p-value | 0.09 | 0.11 | |||
| r | − 0.05 | − 0.08 | 0.09 | − 0.04 | 0.03 |
| p-value | 0.59 | 0.34 | 0.27 | 0.68 | 0.77 |
| r | 0.06 | 0.18 | 0.13 | 0.10 | − 0.05 |
| p-value | 0.52 | 0.13 | 0.24 | 0.55 | |
| r | − 0.20 | 0.18 | − 0.08 | 0.02 | 0.05 |
| p-value | 0.81 | 0.35 | 0.84 | 0.59 | |
| r | 0.01 | 0.17 | − 0.05 | − 0.20 | |
| p-value | 0.94 | 0.56 | |||
OSDI ocular surface disease index, MDEQ McMonnies Dry Eye Questionnaire, TFBUT tear film break-up time, ST Schirmer I Test (mm/5 min), OSS ocular surface staining, ND number of drugs, SXI summated xerostomia inventory, XF xerostomia frequency, UWS unstimulated whole saliva (mL/min), SWS stimulated whole saliva (mL/min).
Bold values represent level of significance: p < 0.05.
Figure 3Loading pattern of the influences of the two factors on DED and dry mouth variables after varimax rotation. MDEQ McMonnies dry eye questionnaire, OSDI Ocular Surface Index questionnaire, TFBUT tear film breakup time (s), OSS ocular surface staining, ST Schirmer I test (mm/5 min). Oral parameters —UWS unstimulated whole saliva (mL/min), SWS stimulated whole saliva (mL/min), CODS clinical oral dryness score, SXI Summated Xerostomia Inventory, ND number of drugs.